oxybenzone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 3412 | 131-57-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 7, 1992 | FDA | BAYER HEALTHCARE LLC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Macular degeneration | 439.42 | 19.25 | 114 | 3092 | 14274 | 50587644 |
| Therapy interrupted | 304.10 | 19.25 | 92 | 3114 | 20060 | 50581858 |
| Death | 181.20 | 19.25 | 155 | 3051 | 325224 | 50276694 |
| Therapy cessation | 161.50 | 19.25 | 61 | 3145 | 25950 | 50575968 |
| Squamous cell carcinoma of skin | 128.97 | 19.25 | 35 | 3171 | 5143 | 50596775 |
| Hospitalisation | 84.75 | 19.25 | 53 | 3153 | 67884 | 50534034 |
| Surgery | 83.74 | 19.25 | 40 | 3166 | 30165 | 50571753 |
| Skin atrophy | 75.24 | 19.25 | 22 | 3184 | 4223 | 50597695 |
| Neoplasm skin | 61.12 | 19.25 | 14 | 3192 | 1026 | 50600892 |
| Ochronosis | 49.82 | 19.25 | 7 | 3199 | 26 | 50601892 |
| Drug ineffective | 48.03 | 19.25 | 136 | 3070 | 819197 | 49782721 |
| Intentional dose omission | 39.25 | 19.25 | 14 | 3192 | 5036 | 50596882 |
| Jarisch-Herxheimer reaction | 22.97 | 19.25 | 5 | 3201 | 290 | 50601628 |
| Chronic sinusitis | 22.86 | 19.25 | 10 | 3196 | 6135 | 50595783 |
| Paraesthesia oral | 21.68 | 19.25 | 12 | 3194 | 12209 | 50589709 |
| Dermatophytosis | 19.92 | 19.25 | 4 | 3202 | 156 | 50601762 |
| Spinal operation | 19.51 | 19.25 | 9 | 3197 | 6251 | 50595667 |
| COVID-19 | 19.35 | 19.25 | 19 | 3187 | 46643 | 50555275 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Death | 277.22 | 27.43 | 184 | 1319 | 341900 | 29231124 |
| Therapy interrupted | 179.94 | 27.43 | 48 | 1455 | 8338 | 29564686 |
| Therapy cessation | 117.12 | 27.43 | 39 | 1464 | 14423 | 29558601 |
| Surgery | 76.67 | 27.43 | 27 | 1476 | 11752 | 29561272 |
| Hospitalisation | 49.16 | 27.43 | 30 | 1473 | 45958 | 29527066 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Therapy interrupted | 494.70 | 18.62 | 136 | 4212 | 19900 | 64474484 |
| Death | 475.13 | 18.62 | 329 | 4019 | 482376 | 64012008 |
| Therapy cessation | 273.93 | 18.62 | 97 | 4251 | 32392 | 64461992 |
| Surgery | 166.91 | 18.62 | 65 | 4283 | 28148 | 64466236 |
| Hospitalisation | 146.42 | 18.62 | 80 | 4268 | 75127 | 64419257 |
| Squamous cell carcinoma of skin | 98.16 | 18.62 | 35 | 4313 | 11841 | 64482543 |
| Skin atrophy | 74.89 | 18.62 | 23 | 4325 | 4897 | 64489487 |
| Neoplasm skin | 58.29 | 18.62 | 14 | 4334 | 1183 | 64493201 |
| Intentional dose omission | 47.98 | 18.62 | 17 | 4331 | 5635 | 64488749 |
| Ochronosis | 47.06 | 18.62 | 7 | 4341 | 39 | 64494345 |
| Spinal operation | 35.75 | 18.62 | 14 | 4334 | 6119 | 64488265 |
| COVID-19 | 32.12 | 18.62 | 30 | 4318 | 65110 | 64429274 |
| Macular degeneration | 26.28 | 18.62 | 11 | 4337 | 5699 | 64488685 |
| Knee operation | 25.15 | 18.62 | 10 | 4338 | 4547 | 64489837 |
| Condition aggravated | 20.23 | 18.62 | 63 | 4285 | 372363 | 64122021 |
| Chronic sinusitis | 18.93 | 18.62 | 9 | 4339 | 6283 | 64488101 |
| Pneumonia | 18.84 | 18.62 | 81 | 4267 | 559495 | 63934889 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D003358 | Cosmetics |
| MeSH PA | D003879 | Dermatologic Agents |
| MeSH PA | D020011 | Protective Agents |
| MeSH PA | D011837 | Radiation-Protective Agents |
| MeSH PA | D013473 | Sunscreening Agents |
| CHEBI has role | CHEBI:35703 | Xenobiotic |
| CHEBI has role | CHEBI:50177 | dermatologic agent |
| CHEBI has role | CHEBI:50267 | protective agents |
| CHEBI has role | CHEBI:73335 | ultraviolet filters |
| CHEBI has role | CHEBI:78298 | environmental contaminants |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.31 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Hormone-sensitive lipase | Enzyme | IC50 | 5.49 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019544 | VUID |
| N0000147648 | NUI |
| D05309 | KEGG_DRUG |
| 4019323 | VANDF |
| 4019544 | VANDF |
| C0069803 | UMLSCUI |
| CHEBI:34283 | CHEBI |
| CHEMBL1625 | ChEMBL_ID |
| DB01428 | DRUGBANK_ID |
| 4632 | PUBCHEM_CID |
| 2096 | INN_ID |
| C005290 | MESH_SUPPLEMENTAL_RECORD_UI |
| 95OOS7VE0Y | UNII |
| 32673 | RXNORM |
| NOCODE | MMSL |
| 001967 | NDDF |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Solbar Thirty SPF 30 | HUMAN OTC DRUG LABEL | 5 | 0096-0685 | CREAM | 0.06 g | TOPICAL | OTC monograph final | 8 sections |
| Solbar Avo SPF35 | HUMAN OTC DRUG LABEL | 4 | 0096-0687 | CREAM | 0.06 g | TOPICAL | OTC monograph final | 8 sections |
| Solbar Fifty SPF50 | HUMAN OTC DRUG LABEL | 4 | 0096-0741 | CREAM | 0.06 g | TOPICAL | OTC monograph final | 8 sections |
| Purpose | HUMAN OTC DRUG LABEL | 3 | 0187-5500 | LOTION | 30 mg | TOPICAL | OTC monograph not final | 9 sections |
| Mederma | HUMAN OTC DRUG LABEL | 3 | 0259-3192 | CREAM | 60 mg | TOPICAL | OTC MONOGRAPH FINAL | 13 sections |
| Mederma | HUMAN OTC DRUG LABEL | 3 | 0259-3192 | CREAM | 60 mg | TOPICAL | OTC MONOGRAPH FINAL | 13 sections |
| Cetaphil Daily Facial Moisturizer with suncreen SPF 50 | HUMAN OTC DRUG LABEL | 5 | 0299-4930 | LOTION | 60 mg | TOPICAL | OTC monograph final | 11 sections |
| Cetaphil Daily Facial Moisturizer with suncreen SPF 50 | HUMAN OTC DRUG LABEL | 5 | 0299-4930 | LOTION | 60 mg | TOPICAL | OTC monograph final | 11 sections |
| Almay Anti Aging Lip Care SPF 20 | HUMAN OTC DRUG LABEL | 5 | 0311-0709 | LIPSTICK | 5 mg | TOPICAL | OTC monograph final | 8 sections |
| Blue Lizard Regular | HUMAN OTC DRUG LABEL | 4 | 0316-2010 | LOTION | 30.60 mg | TOPICAL | OTC monograph final | 8 sections |
| Blue Lizard Sport Original Sunscreen | HUMAN OTC DRUG LABEL | 4 | 0316-2019 | LOTION | 30.60 mg | TOPICAL | OTC monograph not final | 8 sections |
| Walgreens Anti-Sagging and Ultra Hydrating Day Cream Broad Spectrum SPF15 Sunscreen | HUMAN OTC DRUG LABEL | 3 | 0363-0696 | CREAM | 2 g | TOPICAL | OTC monograph not final | 12 sections |
| WALGREEN SPORT SPF 70 SUNSCREEN | HUMAN OTC DRUG LABEL | 5 | 0363-0900 | LOTION | 60 mg | TOPICAL | OTC monograph not final | 12 sections |
| WALGREENS BROAD SPECTRUM SPF 110 AGE PROTECTION SUNSCREEN | HUMAN OTC DRUG LABEL | 5 | 0363-0933 | LOTION | 60 mg | TOPICAL | OTC monograph not final | 12 sections |
| WALGREENS BROAD SPECTRUM SPF 70 SUNSCREEN | HUMAN OTC DRUG LABEL | 5 | 0363-0936 | STICK | 30 mg | TOPICAL | OTC monograph not final | 11 sections |
| WALGREENS SPORT BROAD SPECTRUM SPF 50 FACES SUNSCREEN | HUMAN OTC DRUG LABEL | 5 | 0363-0937 | LOTION | 60 mg | TOPICAL | OTC monograph not final | 13 sections |
| WALGREENS BROAD SPECTRUM SPF 30 DRY TOUCH SUNSCREEN | HUMAN OTC DRUG LABEL | 5 | 0363-0940 | LOTION | 30 mg | TOPICAL | OTC monograph not final | 13 sections |
| Walgreens Sport SPF 50 | HUMAN OTC DRUG LABEL | 5 | 0363-0956 | SPRAY | 50 mg | TOPICAL | OTC monograph not final | 12 sections |
| Walgreens SPF 55 Dry Touch | HUMAN OTC DRUG LABEL | 5 | 0363-0963 | LOTION | 60 mg | TOPICAL | OTC monograph not final | 12 sections |
| Walgreens SPF 50 Clear Complexion For Face | HUMAN OTC DRUG LABEL | 5 | 0363-0981 | LOTION | 45 mg | TOPICAL | OTC monograph not final | 11 sections |
| Walgreens Sport SPF 30 | HUMAN OTC DRUG LABEL | 5 | 0363-0991 | SPRAY | 40 mg | TOPICAL | OTC monograph not final | 13 sections |
| Well at Walgreens Kids Sunscreen Broad Spectrum SPF 50 | HUMAN OTC DRUG LABEL | 5 | 0363-0992 | SPRAY | 50 mg | TOPICAL | OTC monograph not final | 12 sections |
| Well at Walgreens Mist Sheer Broad Spectrum Broad Spectrum SPF 30 | HUMAN OTC DRUG LABEL | 5 | 0363-0996 | SPRAY | 500 mg | TOPICAL | OTC monograph not final | 13 sections |
| Scar with SPF 30Walgreens | HUMAN OTC DRUG LABEL | 3 | 0363-1116 | CREAM | 6 g | TOPICAL | OTC monograph final | 9 sections |
| 70 Dry Touch SPF 70 | HUMAN OTC DRUG LABEL | 5 | 0363-1125 | STICK | 3 g | TOPICAL | OTC monograph not final | 8 sections |
| Walgreens Sunscreen Sport SFP 70 | HUMAN OTC DRUG LABEL | 5 | 0363-1671 | LOTION | 6 g | TOPICAL | OTC monograph not final | 13 sections |
| Walgreens Scar Cream w/SPF 30 | HUMAN OTC DRUG LABEL | 3 | 0363-2054 | CREAM | 60 mg | TOPICAL | OTC monograph final | 12 sections |
| Walgreen Sport SPF 50 | HUMAN OTC DRUG LABEL | 5 | 0363-2720 | LOTION | 6 g | TOPICAL | OTC monograph not final | 13 sections |
| SPF 55 Sport SunstickWell at Walgreens | HUMAN OTC DRUG LABEL | 5 | 0363-3215 | STICK | 6 g | TOPICAL | OTC monograph not final | 10 sections |
| Walgreens Sport Faces SPF 30 | HUMAN OTC DRUG LABEL | 5 | 0363-3890 | LOTION | 4 g | TOPICAL | OTC monograph not final | 13 sections |